Novartis to Seek FDA Emergency Use Approval for New COVID-19 Therapy

Novartis said on Jan. 10 that positive data from a clinical trial of COVID-19 therapeutic drug ensovibep has prompted the firm to exercise an option to in-licence the antiviral from development partner Molecular Partners and later seek emergency use approval from U.S. regulators. Sounds great!

Read more about it

Photo Credit: Andy Holmes